Development of alopecia in patients treated with interleukin‐17 inhibitors

Antoury, Layal; Maloney, Nolan J.; Cheng, Kyle

doi:10.1111/dth.14527

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Paradoxically, there have been reported cases of AA developing during treatment with IL-17 inhibitors. 9 This paradoxical reaction is similar to what has been observed with tumor necrosis factor-alpha (TNF-ɑ) inhibitors, which also induced cutaneous reactions with AA-like manifestations. 10,11 The similarity in clinical presentations between these two groups of biological drugs has prompted the proposal of common underlying mechanisms for their paradoxical effects.…”

Section: Discussionsupporting

confidence: 64%

Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis

Zhang,

Kang,

Qian

et al. 2023

CCID

View full text Add to dashboard Cite

Secukinumab, a monoclonal antibody targeting interleukin-17 , has exhibited encouraging results in the therapeutic management of palmoplantar pustulosis (PPP). The development of alopecia areata (AA) is closely related to IL-17, and IL-17A inhibitors were considered as a potential treatment modality. Therefore, the development of AA during secukinumab treatment for PPP is a rare adverse event that has been rarely reported worldwide. Here we report a 35-year-old female patient with PPP who developed AA after completing the induction period of secukinumab treatment. Discontinuing secukinumab and initiating treatment with tofacitinib resulted in a significant improvement in both PPP and AA. The emergence of AA in this patient can be attributed to paradoxical skin reactions associated with IL-17 inhibitors. Tofacitinib appears to alleviate biologic-induced AA during PPP syndrome treatment.

show abstract

Section: Discussionsupporting

confidence: 64%

Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis

Zhang,

Kang,

Qian

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…The onset of AA has been reported to range from two to 13 months after secukinumab treatment. [3][4][5] The mechanism underlying PRs still needs to be elucidated. However, the modification of the cytokine balance, activation of other inflammatory pathways, and a change in the polarization of T-cell response are suggested hypotheses.…”

mentioning

confidence: 99%

Two paradoxical reactions in a patient with psoriasis and psoriatic arthritis: Adalimumab‐induced hidradenitis suppurativa and secukinumab‐induced alopecia areata

Öğüt

2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Inheritance-Specific Dysregulation of Th1- and Th17-Associated Cytokines in Alopecia Areata

Van Acker,

Schwartz,

Andrews

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Autoimmune diseases tend to cluster in families, suggesting genetic predisposition to autoimmunity associated with familial background. We have previously reported similarities in gene expression patterns and PTPN22 polymorphisms between alopecia areata (AA) patients and their healthy relatives, but not unrelated healthy controls. However, the spectrum of disease promoting (or preventing) pathways that may be activated in blood relatives of AA patients remains to be defined. Here, we investigated the extent to which cytokines associated with the Th1 and Th17 pathway are differentially expressed in the blood of patients with AA and its clinical subtypes in comparison to both healthy relatives as well as unrelated healthy controls. A comprehensive set of Th1- and Th17-related cytokines were evaluated by ELISA. We found a significant elevation of the Th17 inducer IL-23, the Th17 product IL-17A, the Th1 hallmark cytokine IFNγ, and TNFα, a Th1 cytokine with relevance to the Th17 pathway in AA patients, regardless of disease subtype, compared to healthy individuals. On further examination, we found that healthy family members grouped together with patients in terms of elevated Th1- and Th17-pathway cytokines in an inheritance-specific manner, distinct from unrelated controls. The elevation of Th17-associated cytokines in healthy controls related to AA patients indicates that Th1 and Th17 dysregulation in AA may be genetically based. Of note, one unrelated control displayed elevated levels of IL-17A and IL-23 similar to those detected in patients. One year after initial blood draw, areas of beard hair loss consistent with the diagnosis of AA were reported by this individual, indicating that the elevation in Th17-related cytokines may have predictive value.

show abstract

Development of alopecia in patients treated with interleukin‐17 inhibitors

Cited by 3 publications

References 9 publications

Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis

Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis

Two paradoxical reactions in a patient with psoriasis and psoriatic arthritis: Adalimumab‐induced hidradenitis suppurativa and secukinumab‐induced alopecia areata

Inheritance-Specific Dysregulation of Th1- and Th17-Associated Cytokines in Alopecia Areata

Contact Info

Product

Resources

About